Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in skin cells, altering gene expression that controls keratinocyte differentiation and proliferation. This modulation reduces excessive skin cell growth, normalizes epidermal turnover, and diminishes inflammatory processes, leading to clinical improvement in psoriasis and related disorders.

The dosage of Neotigason is individualized by the prescribing clinician based on the severity of the disease, patient weight, and response to therapy. Only a qualified healthcare professional can determine the appropriate dose and schedule; patients should follow the prescriber’s instructions and not adjust the dose on their own.

Neotigason is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe fetal malformations. Women of childbearing potential must use effective contraception during treatment and for at least three years after stopping the drug. Safety during breastfeeding has not been established, so it is generally avoided.

To request Neotigason, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Neotigason (acitretin) belongs to the retinoid class, whereas many other systemic options are biologics or methotrexate. Retinoids act directly on skin cell differentiation, while biologics target immune pathways. Acitretin is oral and does not require injection, but it carries a higher risk of lipid abnormalities and is contraindicated in pregnancy, unlike some alternatives.

Neotigason tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children. Do not refrigerate or freeze the tablets, as temperature extremes can affect their stability.

Neotigason is taken orally, usually with a full glass of water. It is often prescribed to be taken with meals to reduce gastrointestinal irritation, but the exact timing and whether it should be taken with food are determined by the prescribing physician. Patients should swallow the tablet whole and not crush or chew it.

The most serious risks include severe liver toxicity, marked hyperlipidemia, and bone toxicity such as premature closure of growth plates in children. Rare but life‑threatening reactions like Stevens‑Johnson syndrome, toxic epidermal necrolysis, and pseudotumor cerebri have also been reported. Patients should be monitored regularly for these adverse events.

Neotigason should not be used by pregnant women, women who may become pregnant, or those who cannot ensure effective contraception for the required period. It is also contraindicated in patients with severe liver disease, uncontrolled hyperlipidemia, or in growing children due to the risk of affecting bone development. A thorough medical evaluation is required before starting therapy.